Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells

(2015) Parvinder Hothi et al.   Oncotarget

Invasive Glioblastoma Cells Acquire Stemness and Increased Akt Activation

(2015) Jennifer R. Molina et al.   NEOPLASIA

MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib

(2012) Paola Secchiero et al.   BRITISH JOURNAL OF HAEMATOLOGY

Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma

(2012) Roberto E Favoni et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular mechanisms of sorafenib action in liver cancer cells

(2012) Melchiorre Cervello et al.   CELL CYCLE

Metformin selectively affects human glioblastoma tumor-initiating cell viability

(2012) Roberto Würth et al.   CELL CYCLE

The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells

(2012) Tullio Florio et al.   DRUG DISCOVERY TODAY

Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets

(2011) Federica Barbieri et al.   BIOCHEMICAL PHARMACOLOGY

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

(2011) Matija Snuderl et al.   CANCER CELL

Heterogeneity Maintenance in Glioblastoma: A Social Network

(2011) R. Bonavia et al.   CANCER RESEARCH

Pathway inhibition: emerging molecular targets for treating glioblastoma

(2011) W. Wick et al.   NEURO-ONCOLOGY

Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges

(2011) M. Kelly Nicholas et al.   SEMINARS IN ONCOLOGY

Concise Review: Cancer Stem Cells and Minimal Residual Disease

(2011) Gabriel Ghiaur et al.   STEM CELLS

Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation

(2010) R. E. Favoni et al.   CURRENT CANCER DRUG TARGETS

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

(2010) Fan Yang et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib exerts anti-glioma activity in vitro and in vivo

(2010) Markus D. Siegelin et al.   NEUROSCIENCE LETTERS

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell

STAT3 Regulation of Glioblastoma Pathogenesis

(2009) Nuria la Iglesia et al.   CURRENT MOLECULAR MEDICINE

Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors

(2009) Fabrizio Griffero et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation

(2009) J P Robinson et al.   ONCOGENE

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

(2009) R. C. Kane et al.   ONCOLOGIST

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

SOX2Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity

(2008) Rosaria Maria Rita Gangemi et al.   STEM CELLS